Wockhardt Limited has informed the Exchange regarding a press release dated December 11, 2023, titled "Wockhardt announces successful completion of pivotal Phase 3 pneumonia study of its macrolide antibiotic Nafithromycin WCK 4873.".
Wockhardt Limited has informed the Exchange regarding a press release dated December 11, 2023, titled "Wockhardt announces successful completion of pivotal Phase 3 pneumonia study of its macrolide antibiotic Nafithromycin WCK 4873.".